Thr308
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr308  -  Akt1 (human)

Site Information
kDGAtMKtFCGtPEy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447856
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 118 , 257 , 266 , 296 , 316 , 322 , 343 , 369 ) , flow cytometry ( 288 ) , immunoassay ( 132 , 137 ) , immunoprecipitation ( 21 , 23 , 35 , 46 , 51 , 57 , 71 , 95 , 98 , 105 , 113 , 116 , 118 , 123 , 135 , 151 , 154 , 167 , 180 , 196 , 355 ) , mass spectrometry ( 9 , 34 , 41 , 71 , 82 , 83 , 84 , 97 , 102 , 107 , 108 , 124 , 125 , 126 , 127 , 163 , 164 , 165 , 168 , 172 , 182 , 183 , 214 ) , mass spectrometry (in vitro) ( 118 ) , microscopy-colocalization with upstream kinase ( 326 ) , mutation of modification site ( 5 , 6 , 9 , 20 , 35 , 71 , 74 , 80 , 91 , 118 , 178 , 180 , 195 , 205 , 213 , 216 , 230 , 257 , 268 , 276 , 290 , 296 , 322 , 326 , 331 , 348 , 353 , 358 , 367 , 369 ) , peptide sequencing ( 32 , 370 ) , phospho-antibody ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 33 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 60 , 61 , 62 , 63 , 65 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 78 , 79 , 81 , 86 , 89 , 92 , 95 , 96 , 98 , 99 , 101 , 103 , 105 , 106 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 159 , 160 , 161 , 162 , 166 , 167 , 169 , 171 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 181 , 184 , 185 , 186 , 187 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 211 , 212 , 213 , 216 , 218 , 219 , 220 , 221 , 223 , 224 , 225 , 226 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 248 , 249 , 250 , 251 , 252 , 253 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 318 , 319 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 349 , 350 , 351 , 352 , 353 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 371 , 372 ) , phosphoamino acid analysis ( 158 , 369 ) , phosphopeptide mapping ( 322 , 369 ) , western blotting ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 38 , 40 , 41 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 51 , 53 , 54 , 55 , 56 , 57 , 60 , 61 , 62 , 63 , 65 , 67 , 68 , 69 , 70 , 71 , 73 , 74 , 75 , 76 , 78 , 79 , 81 , 86 , 89 , 91 , 92 , 93 , 95 , 96 , 98 , 99 , 101 , 103 , 105 , 106 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 166 , 167 , 169 , 171 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 184 , 185 , 186 , 187 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 210 , 211 , 212 , 213 , 216 , 218 , 219 , 220 , 221 , 223 , 224 , 225 , 226 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 250 , 251 , 252 , 253 , 255 , 259 , 265 , 267 , 269 , 271 , 272 , 273 , 275 , 277 , 279 , 280 , 282 , 283 , 285 , 287 , 289 , 293 , 295 , 296 , 298 , 299 , 302 , 303 , 304 , 307 , 308 , 310 , 313 , 315 , 321 , 322 , 324 , 326 , 327 , 328 , 329 , 331 , 332 , 333 , 335 , 338 , 342 , 351 , 352 , 353 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 364 , 365 , 370 , 371 , 372 )
Disease tissue studied:
adrenal cancer ( 252 ) , pheochromocytoma ( 252 ) , bone cancer ( 81 , 101 , 135 , 159 , 173 , 187 , 190 , 210 , 233 , 248 , 277 , 321 ) , Ewing's sarcoma ( 68 , 210 ) , osteosarcoma ( 248 ) , brain cancer ( 41 , 59 , 129 , 143 , 156 , 173 , 184 , 234 , 239 , 251 , 266 , 357 , 372 ) , astrocytoma ( 266 ) , glioblastoma ( 41 , 59 , 129 , 143 , 173 , 234 , 239 , 251 , 357 ) , glioblastoma multiforme ( 71 , 129 , 184 ) , glioma ( 41 , 59 , 71 , 129 , 143 , 173 , 184 , 234 , 239 , 251 , 357 ) , Schwannoma ( 156 , 372 ) , breast cancer ( 5 , 14 , 21 , 35 , 37 , 49 , 53 , 62 , 71 , 73 , 74 , 89 , 106 , 111 , 113 , 118 , 134 , 138 , 140 , 142 , 143 , 146 , 159 , 167 , 173 , 174 , 186 , 190 , 194 , 200 , 202 , 205 , 206 , 249 , 267 , 269 , 272 , 303 , 327 ) , breast adenocarcinoma ( 74 , 89 , 113 , 159 , 190 ) , HER2 positive breast cancer ( 34 ) , luminal A breast cancer ( 34 ) , luminal B breast cancer ( 34 ) , breast cancer, triple negative ( 34 , 62 , 74 , 89 , 113 , 190 ) , cervical cancer ( 134 , 282 , 298 ) , cervical squamous cell carcinoma ( 298 ) , chondrosarcoma ( 248 ) , colorectal cancer ( 32 , 37 , 72 , 86 , 110 , 118 , 134 , 135 , 140 , 160 , 169 , 192 , 328 , 333 ) , colorectal carcinoma ( 32 , 37 , 72 , 86 , 110 , 118 , 134 , 135 , 140 , 160 , 169 , 192 , 328 , 333 ) , endometrial cancer ( 4 , 145 ) , endometrial adenocarcinoma ( 4 , 145 ) , liposarcoma ( 248 ) , gastric cancer ( 33 , 163 , 164 , 273 ) , gastric carcinoma ( 33 , 163 , 164 , 273 ) , gestational cancer ( 141 ) , gestational trophoblastic choriocarcinoma ( 141 ) , kidney cancer ( 91 , 225 , 255 ) , leukemia ( 8 , 25 , 28 , 31 , 61 , 249 , 359 , 360 ) , acute myelogenous leukemia ( 25 , 28 , 31 , 249 , 359 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 249 , 360 ) , chronic lymphocytic leukemia ( 8 ) , chronic myelogenous leukemia ( 25 ) , T cell leukemia ( 8 ) , liver cancer ( 47 , 50 , 51 , 57 , 154 , 207 , 237 , 271 ) , liver adenocarcinoma ( 50 ) , hepatocellular carcinoma ( 29 , 47 , 57 , 135 , 154 ) , lung cancer ( 11 , 16 , 19 , 39 , 82 , 83 , 84 , 109 , 118 , 135 , 138 , 165 , 173 , 192 , 293 , 347 ) , non-small cell lung cancer ( 11 , 16 , 19 , 22 , 39 , 82 , 84 , 118 , 135 , 165 , 347 ) , non-small cell lung adenocarcinoma ( 11 , 16 , 19 , 39 , 82 , 83 , 84 , 135 , 165 ) , non-small cell large cell lung carcinoma ( 16 , 19 , 84 ) , non-small cell squamous cell lung carcinoma ( 83 , 165 ) , lymphoma ( 20 , 25 , 67 , 78 , 121 , 175 , 244 , 249 , 287 , 313 ) , B cell lymphoma ( 6 , 20 ) , Burkitt's lymphoma ( 287 ) , non-Hodgkin's lymphoma ( 20 ) , mantle cell lymphoma ( 20 ) , PEL ( 67 , 121 ) , T cell lymphoma ( 244 ) , malignant fibrous histiocytoma ( 248 ) , neuroblastoma ( 123 , 133 , 196 , 234 , 240 ) , ovarian cancer ( 23 , 36 , 134 , 140 , 143 , 153 , 156 , 162 , 218 , 303 , 327 ) , ovarian epithelial carcinoma ( 218 ) , pancreatic cancer ( 12 , 22 , 38 , 43 , 95 , 146 , 192 , 275 ) , pancreatic carcinoma ( 12 , 38 , 43 , 95 , 146 , 192 , 275 ) , pancreatic islet cell cancer ( 22 ) , multiple myeloma ( 10 ) , prostate cancer ( 9 , 51 , 78 , 98 , 99 , 105 , 120 , 134 , 140 , 143 , 150 , 176 , 190 , 191 , 204 , 206 , 242 , 245 , 253 , 333 , 358 , 361 ) , Kaposi's sarcoma ( 121 ) , melanoma skin cancer ( 177 , 205 ) , fibrosarcoma of soft tissue ( 60 , 333 ) , leiomyosarcoma ( 145 , 248 ) , rhabdomyosarcoma ( 210 , 219 , 248 , 307 ) , type 2 diabetes ( 139 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 74 ) , 'brain, hippocampus' ( 161 ) , 'macrophage, alveolar'-lung ( 350 ) , 'muscle, skeletal' ( 75 , 79 , 136 , 139 , 144 , 203 , 219 , 260 , 261 , 265 , 271 , 283 ) , 'muscle, smooth' ( 283 ) , 'neuron, dorsal root ganglion'-brain ( 289 ) , 'stem, embryonic' ( 103 , 155 ) , 'stem, mesenchymal' ( 13 ) , 1-LN (prostate cell) ( 98 ) , 22Rv1 (prostate cell) ( 204 ) , 293 (epithelial) [IRS1 (human)] ( 223 ) , 293 (epithelial) ( 46 , 73 , 93 , 95 , 117 , 119 , 150 , 151 , 157 , 171 , 173 , 181 , 184 , 193 , 199 , 213 , 216 , 230 , 232 , 243 , 252 , 256 , 257 , 258 , 270 , 272 , 280 , 290 , 305 , 310 , 315 , 326 , 329 , 330 , 341 , 344 , 349 , 351 , 364 , 370 ) , 293E (epithelial) ( 110 , 321 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 296 , 314 , 324 , 337 ) , 3T3 (fibroblast) ( 51 , 118 , 197 , 212 , 216 , 257 , 362 , 367 ) , 661W ( 152 ) , 786-O (renal) ( 91 ) , A2780 (ovarian) ( 134 , 143 , 218 ) , A375 (melanocyte) ( 177 ) , A431 (epithelial) ( 221 , 280 ) , A549 (pulmonary) ( 11 , 16 , 19 , 109 , 135 , 173 , 192 , 274 , 293 ) , A673 (muscle cell) ( 68 ) , adipocyte ( 371 ) , adipocyte-adipose tissue ( 30 ) , adipose tissue ( 45 ) , AGS (gastric) ( 33 ) , AML10 (myeloid) ( 31 ) , AML11 (myeloid) ( 31 ) , AN3-CA (endometrial) ( 145 ) , aorta ( 338 ) , artery-heart ( 246 ) , Aspc1 (pancreatic) ( 43 ) , BAEC (endothelial) ( 199 , 243 , 335 ) , BaF3 ('B lymphocyte, precursor') ( 28 ) , BC3 (B lymphocyte) ( 67 ) , BEAS-2B (epithelial) ( 40 ) , Ben-Men-1 ( 372 ) , BeWo31 ( 185 ) , BeWo ( 185 ) , bile-duct cell-bile-ducts ( 300 ) , Bon1 (pancreatic) ( 22 ) , BPH-1 (epithelial) ( 150 ) , brain ( 234 ) , breast ( 34 ) , breast cell-breast ( 292 ) , BT-474 (breast cell) ( 37 , 89 , 134 , 138 , 146 , 269 , 281 ) , BT-549 (breast cell) ( 62 , 89 ) , BTIC-12 (glial) ( 59 ) , BTIC-48 (glial) ( 59 ) , BxPC-3 (pancreatic) ( 146 ) , C2C12 (myoblast) [SPRY2 (human), transfection] ( 259 ) , C2C12 (myoblast) ( 259 , 283 , 307 ) , C33-A (cervical) ( 134 , 282 ) , C4-2 (prostate cell) ( 176 ) , Calu-1 (squamous) ( 135 ) , Calu-3 (pulmonary) ( 82 ) , Capan1 (pancreatic) ( 38 ) , CCLP1 (hepatic) ( 300 ) , CD18/HPAF (pancreatic) ( 38 ) , CH27 (squamous) ( 337 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 314 ) , CHO (fibroblast) [EPOR (human)] ( 230 ) , CHO (fibroblast) [INSR (human), transfection] ( 353 ) , CHO (fibroblast) ( 26 , 257 , 285 ) , CHO-K1 (fibroblast) ( 74 ) , COS (fibroblast) ( 197 , 200 , 289 , 296 , 322 , 333 , 341 , 345 , 349 , 355 , 365 , 369 ) , COS7 (fibroblast) ( 144 ) , CTL-EN (T lymphocyte) ( 302 ) , DF1 (fibroblast) ( 233 ) , DLBCL (B lymphocyte) ( 6 ) , DLD1 (intestinal) ( 135 , 169 , 263 ) , DM4 (melanocyte) ( 177 ) , DU 145 (prostate cell) ( 98 , 221 , 361 ) , EA.hy 926 (endothelial) ( 340 ) , embryo ( 233 ) , endothelial-vein ( 348 ) , epithelial-lens ( 148 ) , erythroblast ( 359 ) , ES (stem) ( 252 ) , fibroblast-embryo ( 93 , 178 ) , fibroblast-foreskin ( 71 ) , FL5.12 (lymphoid) ( 212 ) , GI-101A (breast cell) ( 303 , 327 ) , glial-brain ( 41 ) , GM00637 (lymphoblast) ( 276 ) , GM08391 (fibroblast) ( 276 ) , GM09607 (fibroblast) ( 276 ) , GRANTA-519 (B lymphocyte) ( 20 ) , H2009 (pulmonary) ( 63 ) , HaCaT (keratinocyte) ( 27 , 158 , 312 , 346 ) , HAEC (endothelial) ( 208 , 338 ) , HAK-1A (hepatic) ( 29 ) , HAK-1B (hepatic) ( 29 ) , HBL-100 (breast cell) ( 89 ) , HCC (hepatic) ( 135 ) , HCC1428 (breast cell) ( 14 ) , HCC15 (pulmonary) ( 83 ) , HCC1500 (breast cell) ( 14 ) , HCC44 (pulmonary) ( 135 ) , HCC78 (pulmonary) ( 84 ) , HCC827 (pulmonary) ( 82 ) , HCCLM3 (hepatic) ( 47 ) , HCN-2 ('neuron, cortical') ( 179 ) , HCT116 (intestinal) ( 32 , 37 , 86 , 118 , 134 , 135 , 169 , 192 , 263 ) , HCT15 (intestinal) ( 72 ) , heart ( 144 , 159 ) , HEC-50B (endometrial) ( 145 ) , HEI-193 (Schwann) ( 156 , 372 ) , HEK293T (epithelial) ( 24 , 35 , 55 , 80 , 112 , 122 , 135 , 144 , 180 , 195 , 226 , 268 , 269 , 274 , 333 , 334 ) , HeLa (cervical) ( 18 , 51 , 69 , 71 , 74 , 101 , 116 , 118 , 119 , 130 , 131 , 132 , 144 , 166 , 182 , 183 , 221 , 228 , 230 , 241 , 274 , 280 , 297 , 304 ) , hematopoietic progenitor-bone marrow ( 236 ) , Hep 3B2.1-7 (hepatic) ( 300 ) , hepatocyte ( 93 ) , hepatocyte-liver ( 5 , 96 , 299 ) , HepG2 (hepatic) ( 51 , 207 , 237 , 261 , 271 ) , HEY (ovarian) ( 303 , 327 ) , HGC-27 (gastric) ( 33 ) , HL60 (myeloid) ( 25 , 61 , 309 , 316 , 343 ) , HLMVECs ( 70 ) , HPB-ALL (T lymphocyte) ( 313 ) , HS294T (melanocyte) ( 177 ) , HT-29 (intestinal) ( 110 , 140 , 268 , 274 , 311 , 328 ) , HT1080 (fibroblast) ( 60 , 290 , 333 ) , hTERT-RPE1 (epithelial) ( 101 ) , HuCCT1 (hepatic) ( 300 ) , HUES-1 ('stem, embryonic') ( 17 ) , HUES-7 ('stem, embryonic') ( 17 ) , HUES-9 ('stem, embryonic') ( 17 ) , Huh7 (hepatic) ( 154 , 207 ) , HUT-78 (T lymphocyte) ( 244 ) , HUVEC (endothelial) ( 48 , 146 , 193 , 285 , 294 , 318 , 331 , 343 , 345 ) , IGROV1 (ovarian) ( 162 ) , IMR32 (neural crest) ( 234 ) , Ishikawa (endometrial) ( 145 ) , JB (epithelial) ( 295 ) , JEG-3 (uterine) ( 141 ) , JEKO-1 (B lymphocyte) ( 20 ) , Jurkat (T lymphocyte) ( 8 , 102 , 124 , 125 , 126 , 127 , 168 , 172 , 214 , 244 , 264 , 286 , 288 , 313 , 337 ) , K562 (erythroid) ( 25 ) , KB (squamous) ( 298 ) , KELLY (neural crest) ( 234 ) , keratinocyte ( 5 ) , KG-1 (myeloid) ( 249 ) , kidney [KLK1 (human)] ( 225 ) , KLE (endometrial) ( 4 , 145 ) , KPL-1 (breast cell) ( 134 ) , L3.6p1 (pancreatic) ( 38 ) , L6 (myoblast) ( 79 , 223 , 260 , 370 ) , LAN-1 (neural crest) ( 196 ) , leukocyte-blood ( 80 ) , liver ( 7 , 144 , 271 ) , LN-Z308 (glial) ( 239 ) , LN229 (glial) ( 129 ) , LNCaP (prostate cell) ( 99 , 143 , 190 , 204 , 242 , 245 , 358 , 361 ) , LOU-NH91 (squamous) ( 83 ) , LS-513 (intestinal) ( 134 ) , lung ( 82 , 83 , 84 , 159 ) , mammary gland ( 336 ) , MCF-10A (breast cell) [GAB2 (human), transfection] ( 200 ) , MCF-10A (breast cell) ( 73 , 140 , 202 , 327 ) , MCF-7 (breast cell) [CYP19A1 (human)] ( 267 ) , MCF-7 (breast cell) ( 14 , 21 , 71 , 73 , 89 , 106 , 134 , 167 , 173 , 190 , 194 , 205 , 206 , 221 , 249 , 272 ) , MDA-MB-231 (breast cell) ( 5 , 35 , 49 , 53 , 89 , 113 , 118 , 134 , 140 , 142 , 143 , 174 , 186 , 194 , 206 ) , MDA-MB-361 (breast cell) ( 89 , 159 ) , MDA-MB-435 (breast cell) ( 89 , 111 ) , MDA-MB-453 (breast cell) ( 89 ) , MDA-MB-468 (breast cell) ( 74 , 89 , 113 , 190 ) , MEF (fibroblast) ( 46 , 51 , 71 , 110 , 118 , 131 , 135 , 144 , 171 , 180 ) , MEF (fibroblast) [Etk (human), heterozygous knockout] ( 92 ) , MEF (fibroblast) [HRas (human)] ( 250 ) , MEF (fibroblast) [IGF1R (mouse)] ( 303 ) , MEF (fibroblast) [p70S6K (mouse), homozygous knockout] ( 155 ) , MEF (fibroblast) [TSC22D2 (human)] ( 221 ) , MEL624 (melanocyte) ( 177 ) , mesangial ( 279 ) , MeWo (melanocyte) ( 177 ) , MHCC97-L (hepatic) ( 47 ) , MIA PaCa (pancreatic) ( 221 ) , MIA PaCa-2 (pancreatic) ( 192 ) , MKN-45 (gastric) ( 163 , 164 , 273 ) , MOLT-4 (T lymphocyte) ( 244 ) , mononuclear ( 238 ) , mononuclear-blood ( 8 ) , MSN (neuron) ( 291 ) , muscle ( 262 ) , MV4-11 (macrophage) ( 28 , 31 ) , N1 ( 3 ) , NB-4 (myeloid) ( 249 ) , NCI-H1299 (pulmonary) ( 118 ) , NCI-H157 (pulmonary) ( 118 , 268 ) , NCI-H1650 (pulmonary) ( 82 ) , NCI-H1703 (squamous) ( 83 , 165 ) , NCI-H1781 (pulmonary) ( 84 ) , NCI-H1975 (pulmonary) ( 16 , 19 , 39 , 82 ) , NCI-H1993 (pulmonary) ( 135 ) , NCI-H2073 (pulmonary) ( 83 , 135 ) , NCI-H2106 (pulmonary) ( 82 ) , NCI-H2228 (pulmonary) ( 84 ) , NCI-H2342 (pulmonary) ( 83 ) , NCI-H292 (pulmonary) ( 138 ) , NCI-H3122 (pulmonary) ( 84 ) , NCI-H3255 (pulmonary) ( 97 ) , NCI-H345 (pulmonary) ( 284 ) , NCI-H358 (pulmonary) ( 135 ) , NCI-H441 (pulmonary) ( 135 ) , NCI-H460 (pulmonary) ( 16 , 19 , 221 ) , NCI-H510 (pulmonary) ( 284 ) , NCI-H661 (pulmonary) ( 84 ) , NCI-H69 (pulmonary) ( 284 ) , NCI-H727 (epithelial) ( 22 ) , neuron-'brain, hippocampus' ( 161 ) , neutrophil ( 224 , 308 , 342 , 343 , 351 ) , NL-17 (intestinal) ( 333 ) , NSCLC (pulmonary) ( 347 ) , OAW28 (ovarian) ( 23 ) , OCI-ly7 (B lymphocyte) ( 54 ) , OCI/AML3 (myeloid) ( 31 ) , OK (renal) ( 220 ) , oocyte ( 114 ) , ovary ( 153 ) , OVCAR3 (ovarian) ( 23 , 162 ) , OVCAR5 (ovarian) ( 162 ) , PAE (endothelial) ( 46 , 345 ) , PANC-1 (pancreatic) ( 43 , 192 ) , pancreas ( 43 , 275 ) , PC-12 (chromaffin) ( 252 ) , PC3 (prostate cell) ( 9 , 51 , 78 , 98 , 105 , 120 , 134 , 140 , 143 , 176 , 191 , 206 , 221 , 253 , 274 , 333 , 361 ) , platelet-blood ( 231 , 301 , 332 , 356 ) , pp126 (keratinocyte) ( 323 ) , QGP-1 (endocrine) ( 22 ) , RAMOS (B lymphocyte) ( 287 ) , Rh1 (bone cell) ( 210 ) , Rh13 (muscle cell) ( 307 ) , Rh18 (muscle cell) ( 210 , 307 ) , Rh30 ('muscle, skeletal') ( 210 , 219 , 307 ) , Rh4 (muscle cell) ( 307 ) , Rh41 ( 210 ) , Rh5 (muscle cell) ( 307 ) , RPMI-8266 (plasma cell) ( 10 ) , RWP1 (pancreatic) ( 95 ) , Saos-2 (bone cell) ( 256 ) , SB2 (melanocyte) ( 177 ) , SCC12 (keratinocyte) ( 339 ) , Schwann ( 195 ) , SG231 (hepatic) ( 300 ) , SH-SY5Y (neural crest) ( 123 , 133 , 234 , 240 , 305 , 306 ) , SHEP (neuron) ( 234 , 291 ) , SK-HEP-1 (endothelial) ( 50 ) , SK-LU-1 (pulmonary) ( 135 ) , SK-MEL2 (melanocyte) ( 177 ) , SK-MEL28 (melanocyte) ( 44 ) , SK-MEL5 (melanocyte) ( 177 ) , SK-N-BE(2) (neural crest) ( 234 ) , SK-N-MC (neural crest) ( 291 ) , SKBr3 (breast cell) ( 89 , 138 , 281 ) , SKBR7 (breast cell) ( 35 ) , skin ( 27 , 177 ) , SKNSH (neural crest) ( 234 ) , SKOV-3 (ovarian) ( 36 , 140 , 156 , 162 , 322 ) , SKRC-44 (renal) ( 255 ) , SKUT-1 ( 145 ) , SMMC7721 (hepatocyte) ( 50 ) , SRB-1 (squamous) ( 312 ) , SU-DHL-2 (B lymphocyte) ( 54 ) , Su.86.86 (pancreatic) ( 12 , 43 ) , SUM149 (breast cell) ( 37 ) , SW1463 (intestinal) ( 134 ) , SW48 (intestinal) ( 72 ) , SW620 (intestinal) ( 72 ) , T lymphocyte-blood ( 229 ) , T47D (breast cell) ( 14 , 21 , 71 , 89 , 134 , 303 ) , T84 (intestinal) ( 160 ) , T98G (glial) ( 71 , 129 ) , TF-1 (erythroid) ( 249 , 360 ) , THP1 (myeloid) ( 25 , 352 ) , U-251 MG (glial) ( 239 , 251 ) , U-937 (myeloid) ( 25 , 78 , 175 , 249 , 313 ) , U2OS (bone cell) [GR (human)] ( 321 ) , U2OS (bone cell) ( 81 , 101 , 135 , 159 , 173 , 187 , 190 , 233 , 277 ) , U373 MG (glial) ( 184 ) , U87MG (glial) ( 143 , 173 , 234 , 251 , 266 , 357 ) , UACC-257 (melanocyte) ( 177 ) , UCSD-354L (melanocyte) ( 177 ) , UT-7 (myeloid) [EPO (human), transfection] ( 359 ) , VSMC-aorta ( 149 ) , WI-38 (fibroblast) ( 190 ) , WiDr (epithelial) ( 32 ) , WM-1552 (melanocyte) ( 177 ) , WM1799 (melanocyte) ( 177 ) , WM2664 (melanocyte) ( 177 ) , WM3211 (melanocyte) ( 177 ) , WM35 (melanocyte) ( 177 , 205 ) , WM46 (melanocyte) ( 177 ) , WM793 ( 140 ) , ZR-75-1 (breast cell) ( 89 )

Upstream Regulation
Regulatory protein:
Ack (human) ( 47 ) , ADRA1B (human) ( 320 ) , Akt1 (human) ( 106 , 114 , 140 , 181 , 197 , 211 , 329 , 357 ) , Akt2 (human) ( 181 , 197 ) , AMIGO2 (human) ( 48 ) , APPL (mouse) ( 96 ) , BAP28 (human) ( 43 ) , Bcr (human) ( 6 ) , beclin 1 (human) ( 49 ) , BRAF (human) ( 177 ) , Brk (human) ( 105 , 150 ) , CA9 (human) ( 255 ) , CAMKK1 (human) ( 329 ) , CD133 (human) ( 55 ) , CDK1 (human) ( 17 ) , CHKA (human) ( 194 ) , CHKB (human) ( 194 ) , CIP2A (human) ( 73 ) , CSF2RB (human) ( 302 ) , CYP3A5 (human) ( 57 ) , DDIT4 (human) ( 270 ) , DDIT4L (human) ( 270 ) , DYRK2 (human) ( 21 ) , Epac1 (human) ( 98 ) , ERK1 (human) ( 230 ) , ERK2 (human) ( 230 ) , Etk (human) ( 92 ) , FKBP5 (human) ( 4 ) , FRK (human) ( 187 ) , GAB2 (human) ( 200 ) , GRB2 (human) ( 149 ) , GRP78 (human) ( 141 ) , GSK3A (human) ( 113 ) , HER2 (human) ( 89 ) , HER3 (human) ( 162 ) , HRas (human) ( 140 , 278 , 320 , 362 ) , HSP90A (human) ( 213 ) , IEX-1 (human) ( 230 ) , IKKB (human) ( 203 ) , IKKE (human) ( 118 ) , IL24 (human) ( 52 ) , IL2RA (human) ( 229 ) , ILK (human) ( 206 , 251 , 304 , 310 , 361 ) , INPP4B (human) ( 32 ) , INPP5E (human) ( 334 ) , IRS2 (human) ( 93 ) , KLK1 (human) ( 225 ) , KRas (human) ( 135 , 278 ) , LIMS1 (human) ( 304 ) , LKB1 (human) ( 228 ) , LYN (human) ( 209 ) , MEK1 (human) ( 327 ) , Met (human) ( 70 ) , MINK (human) ( 35 ) , MST2 (human) ( 156 ) , mTOR (human) ( 114 , 181 , 208 ) , MYO6 (human) ( 11 ) , NRas (human) ( 177 ) , OSBPL9 (human) ( 232 ) , P130Cas (human) ( 88 ) , p300 (human) ( 144 ) , p53 (human) ( 190 ) , PAK1 (human) ( 241 ) , PAK1 (rat) ( 197 ) , PAK2 (human) ( 197 , 241 ) , PCAF (human) ( 144 ) , PCTP (human) ( 93 ) , PDK1 (human) ( 118 , 135 , 171 , 213 , 326 ) , PDK1 (mouse) ( 283 , 353 ) , PHLDA3 (human) ( 190 ) , PHLPP (human) ( 110 , 140 , 227 ) , PHLPP2 (human) ( 110 , 140 , 227 ) , PIK3CA (human) ( 140 , 202 , 238 ) , PIK3CG (human) ( 289 ) , PIK3R1 (human) ( 9 , 118 ) , PIK3R2 (human) ( 70 ) , PINK1 (human) ( 133 ) , PKACA (mouse) ( 96 ) , PKCB (human) ( 238 ) , PKCT (mouse) ( 91 ) , PKN1 (human) ( 353 ) , PKN2 (human) ( 353 , 355 ) , PPP1CA (human) ( 148 ) , PPP1R2 (human) ( 240 ) , PPP2CA (human) ( 110 , 166 , 212 ) , PPP2R2A (human) ( 25 , 38 , 40 ) , PPP2R5B (human) ( 230 ) , PRICKLE1 (human) ( 35 ) , PTEN (human) ( 62 , 134 , 233 , 357 , 361 , 362 ) , PTPRJ (human) ( 193 ) , PTPRK (human) ( 55 ) , PXN iso2 (human) ( 169 ) , RAC1 (human) ( 197 ) , Raptor (human) ( 73 , 181 ) , RHEBL1 (human) ( 15 ) , RICTOR (human) ( 135 , 181 , 191 ) , RRas (human) ( 140 ) , SHIP (human) ( 286 ) , SHIP-2 (human) ( 140 ) , SHIP-2 (mouse) ( 357 ) , SHP-1 (human) ( 117 ) , SHPS1 (human) ( 149 ) , Sin1 (human) ( 135 ) , SIRT1 (human) ( 74 , 144 ) , SIRT2 (human) ( 74 ) , SPRY2 (human) ( 259 ) , Src (human) ( 211 , 320 ) , ST3GAL5 (human) ( 61 ) , ST8SIA1 (human) ( 61 ) , TACC3 (human) ( 50 ) , THEM2 (human) ( 93 ) , TIMP1 (human) ( 63 ) , TRAF6 (human) ( 180 ) , ULK1 (human) ( 226 ) , USP49 (human) ( 12 ) , ZFP57 (human) ( 60 )
Putative in vivo kinases:
AXL (human) ( 26 ) , IKKE (human) ( 118 ) , Mer (human) ( 26 ) , PDK1 (human) ( 51 , 134 , 149 , 328 , 333 ) , PIK3CA (human) ( 93 ) , PRKD1 (human) ( 326 ) , TBK1 (human) ( 135 ) , Tyro3 (human) ( 26 )
Kinases, in vitro:
IKKE (human) ( 118 ) , PDK1 (human) ( 254 , 274 , 333 , 363 , 368 ) , PKCA (human) ( 356 ) , PKCB (human) ( 356 ) , TBK1 (human) ( 135 )
Putative upstream phosphatases:
PPP2CA (human) ( 43 , 186 ) , PTEN (human) ( 23 )
Phosphatases, in vitro:
PPP2CA (human) ( 212 ) , PTEN (human) ( 23 )
Treatments:
1-methyladenine ( 114 ) , 2-deoxyglucose ( 298 ) , 4-DAMP ( 99 ) , 4-HT ( 174 , 211 , 326 ) , 5-cholesten-5-beta-ol ( 158 ) , 8-CPT-2Me-cAMP ( 98 ) , 8-Rp-cAMP ( 246 ) , 9cRA ( 174 ) , A-443654 ( 154 ) , actinomycin_D ( 155 ) , activin ( 103 ) , ADA ( 224 ) , adiponectin ( 186 , 228 ) , adriamycin ( 180 ) , afatinib ( 39 ) , AG1024 ( 303 ) , AG1296 ( 303 ) , AG1478 ( 133 , 158 , 280 , 303 ) , AGK2 ( 74 ) , Akt-I-1 ( 166 , 220 , 282 ) , Akt-I-1,2 ( 282 ) , Akt_inhibitor_VIII ( 133 , 151 ) , alpelisib ( 22 ) , alpha-mangostin ( 142 ) , amino_acids ( 260 , 321 ) , angiotensin ( 294 ) , anti-Akt1 ( 269 ) , anti-CD3/CD28 ( 229 ) , anti-E-cadherin ( 323 ) , anti-HER2 ( 281 ) , anti-HLA ( 208 ) , anti-ICAM-2 ( 337 ) , anti-IgM ( 20 , 238 ) , anti-integrin_alpha9beta1 ( 140 ) , anti-PDGFR ( 303 ) , apelin ( 285 ) , API-2 ( 118 ) , arachidonic_acid ( 343 ) , atiprimod ( 237 ) , AZD8055 ( 173 ) , BAPTA-AM ( 253 , 301 , 356 ) , BAR501 ( 64 ) , BCI-121 ( 24 ) , BDNF ( 59 ) , bisindolylmaleimide ( 238 , 356 ) , BQ-123 ( 280 ) , BQ-788 ( 280 ) , bradykinin ( 345 ) , bumetanide ( 235 ) , C2-ceramide ( 353 ) , C6-ceramide ( 36 , 360 ) , caffeine ( 295 ) , calyculin_A ( 140 , 231 , 235 , 246 , 253 , 360 ) , cAMP_analog ( 195 ) , cangrelor ( 301 ) , carbachol ( 99 ) , CAY10399 ( 224 ) , CCCP ( 305 ) , celastrol ( 78 ) , celecoxib ( 300 , 328 ) , cell_adhesion ( 175 ) , CGS_21680 ( 224 ) , cholesterol ( 158 ) , cholesterol_oxidase ( 158 ) , ciclosporin ( 129 , 253 ) , cisplatin ( 180 ) , colforsin ( 195 , 224 , 246 , 349 ) , collagen ( 332 ) , collagen XIX (NC1 domain) ( 44 ) , compound_7 ( 134 ) , conditioned medium ( 31 ) , convulxin ( 332 ) , CTGF ( 279 ) , culturing_of_cells ( 161 , 238 ) , CXCL12 ( 238 , 241 ) , cyclic_stretch ( 280 ) , cycloheximide ( 116 ) , dactolisib ( 104 , 202 ) , dasatinib ( 140 ) , decorin ( 340 ) , deoxygenation ( 76 ) , depolarization ( 240 ) , derivative-2 ( 67 ) , dexamethasone ( 174 ) , DMSO ( 202 , 211 ) , dronabinol ( 244 ) , duvelisib ( 31 ) , EF24 ( 218 ) , EGF ( 5 , 11 , 36 , 74 , 110 , 113 , 133 , 135 , 150 , 156 , 200 , 227 , 242 , 245 , 255 , 283 , 295 , 303 , 311 , 349 ) , EGTA ( 99 ) , englerin_A ( 91 ) , ephrin_A1 ( 140 , 184 ) , Epo ( 230 , 359 ) , erbstatin ( 338 ) , erlotinib ( 56 ) , estrogen_deprivation ( 267 ) , ethanol ( 140 , 323 ) , exercise training ( 139 ) , fasting ( 75 ) , FGF2 ( 103 , 259 ) , fibronectin ( 86 ) , Filipin ( 158 ) , fingolimod ( 25 , 28 , 313 ) , FL ( 28 ) , fluid_shear_stress ( 335 ) , FMK-MEA ( 72 ) , fMLP ( 224 , 342 , 343 ) , FTI277 ( 278 ) , ganglioside ( 339 ) , gefitinib ( 56 , 97 ) , genistein ( 338 ) , GF109203X ( 285 , 301 ) , GH ( 75 ) , ghrelin ( 117 ) , glabridin ( 109 ) , glucose ( 135 , 201 ) , glucose_starvation ( 223 ) , GM-CSF ( 360 ) , Go_6976 ( 356 ) , growth_factor_withdrawal ( 152 ) , GSK2334470 ( 10 , 14 , 51 ) , GSK690693 ( 118 ) , H-89 ( 224 , 320 ) , H2O2 ( 151 , 152 , 171 , 199 , 235 ) , heat_shock ( 296 , 305 ) , hepatitis C virus expression ( 7 ) , heregulin ( 103 ) , HGF ( 33 , 57 , 70 , 86 , 299 ) , high-fat diet ( 117 , 371 ) , HNMPA(AM)3 ( 179 ) , HU-210 ( 317 ) , hypotonic_buffer ( 235 ) , hypoxia ( 185 ) , hypoxia/reoxygenation ( 254 ) , ibrutinib ( 8 , 54 ) , IC87114 ( 224 ) , ICAM-2 ( 337 ) , idelalisib ( 20 ) , IFN-gamma ( 160 ) , IGF-1 ( 49 , 103 , 147 , 149 , 167 , 180 , 210 , 216 , 235 , 258 , 272 , 303 , 304 , 305 , 322 , 347 , 370 ) , IGF-2 ( 60 , 307 ) , IgG ( 323 ) , IL-13 ( 328 ) , IL-1a ( 94 ) , IL-1b ( 180 , 329 ) , IL-3 ( 212 ) , IL-6 ( 261 ) , imatinib ( 140 ) , insulin ( 30 , 74 , 79 , 93 , 96 , 110 , 116 , 118 , 122 , 135 , 136 , 139 , 151 , 154 , 166 , 181 , 189 , 207 , 221 , 223 , 226 , 228 , 259 , 260 , 261 , 262 , 268 , 271 , 276 , 283 , 294 , 298 , 305 , 314 , 315 , 319 , 321 , 324 , 330 , 338 , 341 , 344 , 353 , 370 , 371 ) , ionomycin ( 99 , 329 ) , IP(6) ( 176 ) , IQA ( 264 ) , isoproterenol ( 320 ) , isosilybin_B ( 204 ) , K252a ( 279 ) , KCl ( 235 ) , KHS101 ( 50 ) , KN-93 ( 99 ) , KP-372-1 ( 249 ) , KP-392 ( 361 ) , KU-0063794 ( 78 ) , LAM ( 352 ) , laminin-1 ( 86 ) , leptin ( 338 ) , linoleic_acid ( 79 ) , losartan ( 280 , 294 ) , low_glucose ( 144 ) , LPA ( 303 , 327 ) , LPS ( 45 , 135 , 180 , 350 ) , LY294002 ( 70 , 74 , 101 , 103 , 116 , 118 , 135 , 140 , 158 , 166 , 167 , 194 , 201 , 216 , 221 , 230 , 236 , 238 , 242 , 244 , 245 , 246 , 257 , 264 , 268 , 280 , 297 , 299 , 301 , 309 , 316 , 317 , 320 , 323 , 326 , 327 , 332 , 338 , 346 , 347 , 350 , 353 , 354 , 356 , 357 , 360 ) , LY333531 ( 238 ) , major_basic_protein ( 308 ) , mastoparan ( 317 ) , methyl-beta-cyclodextrin ( 158 ) , MG132 ( 243 ) , MK-2206 ( 25 , 59 , 101 , 118 ) , Mn(2+) ( 140 ) , N6-benzoyl-cAMP ( 98 ) , NAC ( 152 ) , naltrindole ( 284 ) , neuregulin ( 162 , 195 ) , neurotrophin-3 ( 59 ) , NGF ( 252 , 306 ) , nicotinamide ( 74 , 144 ) , nicotine ( 293 ) , NS398 ( 273 ) , okadaic_acid ( 43 , 114 , 116 , 119 , 140 , 152 , 166 , 175 , 186 , 243 , 253 , 268 , 313 , 360 ) , oleic_acid ( 79 ) , OSI-027 ( 104 ) , OSU-03012 ( 41 , 219 ) , OSU-T315 ( 372 ) , ouabain ( 220 ) , PAR1-activating_peptide ( 301 ) , PAR4-activating_peptide ( 301 ) , PD0325901 ( 72 ) , PD168393 ( 280 ) , PD98059 ( 140 , 257 , 316 , 327 , 342 ) , PDGF ( 169 , 197 , 216 , 295 , 296 , 303 , 334 , 367 ) , PDK1_inhibitor_3 ( 143 ) , pemetrexed ( 16 , 19 , 37 ) , perifosine ( 118 ) , PGE2 ( 224 ) , phorbol_ester ( 65 , 235 , 236 , 238 , 301 , 315 , 321 , 344 , 356 ) , PI-103 ( 133 , 202 ) , pictilisib ( 93 ) , PIK-93 ( 202 ) , PIK90 ( 202 ) , pimenta doica ( 53 ) , PKC_inhibitor_myristoylated ( 285 ) , PKI-402 ( 159 ) , PLS-123 ( 54 ) , PLTP ( 179 ) , PP-110 ( 202 ) , PP1 ( 257 ) , PP2 ( 140 , 193 , 320 ) , PP242 ( 10 , 72 , 147 , 155 , 189 ) , PP30 ( 189 ) , PTP1B_inhibitor ( 122 ) , PTX ( 280 , 285 , 327 ) , PUGNAc ( 106 ) , QLT0254 ( 275 ) , racepinefrine ( 99 , 136 ) , rapamycin ( 29 , 72 , 93 , 110 , 140 , 147 , 155 , 173 , 205 , 210 , 228 , 257 , 285 , 298 , 321 , 354 ) , resveratrol ( 144 , 151 ) , retinoic_acid ( 155 , 174 ) , rimonabant ( 317 ) , Ro31-8220 ( 236 ) , salicylate ( 315 , 354 ) , sardomozide ( 196 ) , SB203580 ( 327 , 351 ) , SCF ( 236 ) , scratch wound ( 76 ) , selenite ( 253 ) , serum ( 3 , 101 , 180 , 184 , 197 , 202 , 212 , 221 , 239 , 245 , 256 , 295 , 347 , 361 ) , serum_starvation ( 132 , 230 ) , serum_withdrawal ( 250 ) , SH-5 ( 238 ) , SH-6 ( 239 , 285 ) , sildenafil ( 16 , 19 ) , silmitasertib ( 120 , 146 ) , simvastatin ( 158 ) , SiO2 @AM/CN ( 18 ) , siRNA ( 118 , 135 , 193 , 197 , 203 , 206 , 209 , 218 , 227 , 232 , 241 , 304 ) , sonolisib ( 58 ) , sorafenib ( 16 , 37 ) , sorbitol ( 235 ) , SP600125 ( 78 , 254 , 315 ) , sphingosine_1-phosphate ( 303 , 327 ) , sphingosylphosphorylcholine ( 15 ) , starvation_medium ( 103 ) , staurosporine ( 78 , 272 , 333 , 344 ) , STO-609 ( 99 ) , Su11274 ( 70 ) , SU6656 ( 211 ) , tamoxifen ( 174 , 211 ) , tautomycetin ( 166 ) , tautomycin ( 140 ) , TBB ( 264 ) , temsirolimus ( 145 ) , TGF-alpha ( 5 ) , TGF-beta ( 9 ) , thapsigargin ( 96 ) , thrombin ( 301 , 332 , 356 ) , TNF ( 160 , 203 , 207 , 235 , 280 , 315 ) , Torin1 ( 65 , 111 , 112 ) , TPO ( 230 , 356 ) , tunicamycin ( 141 ) , U0126 ( 65 , 220 , 244 , 298 ) , UCN-01 ( 154 , 291 , 333 ) , UV ( 346 ) , V-100 ( 254 ) , valproic_acid ( 23 ) , vanadate ( 213 , 235 , 322 , 341 ) , VEGF ( 48 ) , virus infection ( 135 , 207 , 256 , 324 ) , wortmannin ( 78 , 93 , 118 , 133 , 158 , 199 , 224 , 257 , 280 , 285 , 296 , 298 , 307 , 311 , 316 , 317 , 321 , 327 , 332 , 335 , 338 , 342 , 347 , 349 , 350 , 353 , 355 , 370 )

Downstream Regulation
Effects of modification on Akt1:
activity, induced ( 281 , 288 , 305 , 323 , 347 , 352 , 369 ) , enzymatic activity, induced ( 51 , 74 , 93 , 118 , 132 , 178 , 197 , 201 , 256 , 296 , 301 , 309 , 311 , 316 , 346 , 362 , 367 , 368 , 370 ) , intracellular localization ( 153 , 159 , 197 , 216 , 305 , 357 ) , molecular association, regulation ( 9 , 197 , 256 , 369 ) , phosphorylation ( 114 , 135 , 144 , 353 ) , protein conformation ( 216 )
Effects of modification on biological processes:
apoptosis, altered ( 149 ) , apoptosis, inhibited ( 135 , 146 , 347 , 355 ) , carcinogenesis, induced ( 118 , 135 , 146 , 177 ) , cell cycle regulation ( 146 , 281 ) , cell growth, altered ( 160 , 212 ) , cell growth, induced ( 32 , 59 , 146 ) , cell growth, inhibited ( 159 ) , cell motility, altered ( 197 , 331 ) , cell motility, induced ( 70 , 146 ) , cytoskeletal reorganization ( 348 ) , signaling pathway regulation ( 70 , 79 , 135 , 146 ) , transcription, altered ( 346 ) , transcription, induced ( 80 )
Induce interaction with:
PAK1 (human) ( 197 ) , PDK1 (human) ( 197 ) , PPP2CA (human) ( 256 ) , TGFBR3 (human) ( 9 ) , TRAF6 (human) ( 9 )

Disease / Diagnostics Relevance
Relevant diseases:
HNSCC ( 137 ) , chronic lymphocytic leukemia ( 238 ) , neuroblastoma ( 234 ) , ovarian cancer ( 153 ) , pancreatic cancer ( 43 ) , Kaposi's sarcoma ( 121 ) , melanoma skin cancer ( 177 ) , rhabdomyosarcoma ( 219 ) , diabetes mellitus ( 225 ) , type 2 diabetes ( 139 , 265 )

References 

1

Miller WP, et al. (2020) The stress response protein REDD1 promotes diabetes-induced oxidative stress in the retina by Keap1-independent Nrf2 degradation. J Biol Chem
32295843   Curated Info

2

Han F, et al. (2018) The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance. Nat Commun 9, 4728
30413706   Curated Info

3

Ohmi Y, et al. (2018) Differential roles of gangliosides in malignant properties of melanomas. PLoS One 13, e0206881
30462668   Curated Info

4

Dong J, et al. (2017) FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt. Oncotarget 8, 80405-80415
29113312   Curated Info

5

Guo J, et al. (2017) PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion. Mol Cell Biol 37
28674187   Curated Info

6

Havranek O, et al. (2017) Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood 130, 995-1006
28646116   Curated Info

7

Lerat H, et al. (2017) Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem 292, 12860-12873
28559285   Curated Info

8

Patel V, et al. (2017) Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res 23, 3734-3743
28034907   Curated Info

9

Hamidi A, et al. (2017) TGF-β promotes PI3K-AKT signaling and prostate cancer cell migration through the TRAF6-mediated ubiquitylation of p85α. Sci Signal 10
28676490   Curated Info

10

Yang C, et al. (2017) PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget 8, 39185-39197
28402933   Curated Info

11

Masters TA, Tumbarello DA, Chibalina MV, Buss F (2017) MYO6 Regulates Spatial Organization of Signaling Endosomes Driving AKT Activation and Actin Dynamics. Cell Rep 19, 2088-2101
28591580   Curated Info

12

Luo K, et al. (2017) USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J 36, 1434-1446
28363942   Curated Info

13

Chen YX, et al. (2017) Novel Akt activator SC-79 is a potential treatment for alcohol-induced osteonecrosis of the femoral head. Oncotarget 8, 31065-31078
28415692   Curated Info

14

Jansen VM, et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77, 2488-2499
28249908   Curated Info

15

Kim HJ, et al. (2017) Novel involvement of RhebL1 in sphingosylphosphorylcholine-induced keratin phosphorylation and reorganization: Binding to and activation of AKT1. Oncotarget 8, 20851-20864
28209923   Curated Info

16

Booth L, Roberts JL, Poklepovic A, Dent P (2017) PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget 8, 13464-13475
28088782   Curated Info

17

Wang XQ, et al. (2017) CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ 24, 38-48
27636107   Curated Info

18

Dehghany Ashkezary M, Aboee-Mehrizi F, Moradi P (2017) SiO2@antisense molecules covered by nepetalactone, extracted from Nepeta gloeocephala, inhibits ILK phosphorylation and downstream PKB/AKT signaling in HeLa cells. Cancer Gene Ther 24, 28-32
27982018   Curated Info

19

Booth L, et al. (2017) PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget 8, 1449-1468
27903966   Curated Info

20

Yang Q, et al. (2017) Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res 23, 181-192
27342398   Curated Info

21

Mimoto R, et al. (2017) Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR. Cancer Lett 384, 27-38
27746162   Curated Info

22

Nölting S, et al. (2017) The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS One 12, e0182852
28800359   Curated Info

23

Phadngam S, et al. (2016) PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Oncotarget 7, 84999-85020
27829222   Curated Info

24

Yoshioka Y, et al. (2016) SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget 7, 75023-75037
27626683   Curated Info

25

Shouse G, et al. (2016) Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget 7, 61081-61092
27531894   Curated Info

26

Kimani SG, et al. (2016) Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal 14, 19
27595981   Curated Info

27

Choi YJ, et al. (2016) The underlying mechanism of proinflammatory NF-κB activation by the mTORC2/Akt/IKKα pathway during skin aging. Oncotarget 7, 52685-52694
27486771   Curated Info

28

Smith AM, et al. (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget 7, 47465-47478
27329844   Curated Info

29

Watari K, et al. (2016) Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 7, 47403-47417
27329724   Curated Info

30

Rajan MR, et al. (2016) Systems-wide Experimental and Modeling Analysis of Insulin Signaling through Forkhead Box Protein O1 (FOXO1) in Human Adipocytes, Normally and in Type 2 Diabetes. J Biol Chem 291, 15806-15819
27226562   Curated Info

31

Pillinger G, et al. (2016) Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget 7, 39784-39795
27174919   Curated Info

32

Guo ST, et al. (2016) INPP4B is an oncogenic regulator in human colon cancer. Oncogene 35, 3049-61
26411369   Curated Info

33

Wu Y, et al. (2016) PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells. Oncotarget 7, 34190-200
27147579   Curated Info

34

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

35

Daulat AM, et al. (2016) PRICKLE1 Contributes to Cancer Cell Dissemination through Its Interaction with mTORC2. Dev Cell 37, 311-25
27184734   Curated Info

36

Kitatani K, et al. (2016) Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene 35, 2801-12
26364609   Curated Info

37

Booth L, et al. (2016) [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget 7, 23608-32
27015562   Curated Info

38

Hein AL, et al. (2016) PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res 76, 2243-53
26893480   Curated Info

39

Booth L, et al. (2016) The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 7, 19620-30
26934000   Curated Info

40

Bousquet E, et al. (2016) RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene 35, 1760-9
26148238   Curated Info

41

Booth L, et al. (2016) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7, 12975-96
26887051   Curated Info

42

Lin CH, Liu SY, Lee EH (2016) SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene 35, 595-607
25867063   Curated Info

43

Liu T, et al. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res 76, 572-81
26676747   Curated Info

44

Oudart JB, et al. (2016) The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction. Oncotarget 7, 1516-28
26621838   Curated Info

45

Rittig N, et al. (2016) Regulation of Lipolysis and Adipose Tissue Signaling during Acute Endotoxin-Induced Inflammation: A Human Randomized Crossover Trial. PLoS One 11, e0162167
27627109   Curated Info

46

Frías A, et al. (2015) A Switch in Akt Isoforms Is Required for Notch-Induced Snail1 Expression and Protection from Cell Death. Mol Cell Biol 36, 923-40
26711268   Curated Info

47

Lei X, et al. (2015) Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget 6, 40622-41
26536663   Curated Info

48

Park H, et al. (2015) AMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation. J Cell Biol 211, 619-37
26553931   Curated Info

49

Rohatgi RA, et al. (2015) Beclin 1 regulates growth factor receptor signaling in breast cancer. Oncogene 34, 5352-62
25639875   Curated Info

50

Zhou DS, et al. (2015) TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget 6, 24163-77
26219398   Curated Info

51

Yang G, Murashige DS, Humphrey SJ, James DE (2015) A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation. Cell Rep 12, 937-43
26235620   Curated Info

52

Panneerselvam J, et al. (2015) Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget 6, 16271-86
26009991   Curated Info

53

Zhang L, et al. (2015) Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice. Oncotarget 6, 16379-95
25945840   Curated Info

54

Ding N, et al. (2015) Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget 6, 15122-36
25944695   Curated Info

55

Shimozato O, et al. (2015) Receptor-type protein tyrosine phosphatase κ directly dephosphorylates CD133 and regulates downstream AKT activation. Oncogene 34, 1949-60
24882578   Curated Info

56

Kim Y, et al. (2015) Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors. Mol Cancer Res 13, 765-74
25573954   Curated Info

57

Jiang F, et al. (2015) CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling. Cancer Res 75, 1470-81
25649767   Curated Info

58

Ghosh JC, et al. (2015) Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst 107
25650317   Curated Info

59

Lawn S, et al. (2015) Neurotrophin signaling via TrkB and TrkC receptors promotes the growth of brain tumor-initiating cells. J Biol Chem 290, 3814-24
25538243   Curated Info

60

Tada Y, et al. (2015) The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells. Oncogene 34, 752-60
24469060   Curated Info

61

Ma H, et al. (2015) Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia. Oncogene 34, 726-40
24531716   Curated Info

62

Mense SM, et al. (2015) PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Sci Signal 8, ra32
25829446   Curated Info

63

Nalluri S, et al. (2015) TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2. PLoS One 10, e0137673
26366732   Curated Info

64

Renga B, et al. (2015) Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 10, e0141082
26539823   Curated Info

65

Leontieva OV, Blagosklonny MV (2014) Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion. Oncotarget 5, 12715-27
25587030   Curated Info

66

Humphrey RK, et al. (2014) Loss of TRB3 Alters Dynamics of MLK3-JNK Signaling and Inhibits Cytokine-activated Pancreatic Beta Cell Death. J Biol Chem 289, 29994-30004
25204656   Curated Info

67

Watanabe T, et al. (2014) Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma. Biochem Biophys Res Commun 451, 93-100
25063029   Curated Info

68

Niedan S, et al. (2014) Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Oncogene 33, 3927-38
23995784   Curated Info

69

Saha A, et al. (2014) Akt phosphorylation and regulation of transketolase is a nodal point for amino Acid control of purine synthesis. Mol Cell 55, 264-76
24981175   Curated Info

70

Usatyuk PV, et al. (2014) Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem 289, 13476-91
24634221   Curated Info

71

Liu P, et al. (2014) Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 508, 541-5
24670654   Curated Info

72

Ducker GS, et al. (2014) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590-600
23542178   Curated Info

73

Puustinen P, et al. (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-27
24590173   Curated Info

74

Ramakrishnan G, et al. (2014) Sirt2 Deacetylase Is a Novel AKT Binding Partner Critical for AKT Activation by Insulin. J Biol Chem 289, 6054-66
24446434   Curated Info

75

Nellemann B, et al. (2014) Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol (Oxf) 210, 392-402
24148194   Curated Info

76

Dunn CA, Lampe PD (2014) Injury-triggered Akt phosphorylation of Cx43: a ZO-1-driven molecular switch that regulates gap junction size. J Cell Sci 127, 455-64
24213533   Curated Info

77

Treebak JT, et al. (2014) Acute exercise and physiological insulin induce distinct phosphorylation signatures on TBC1D1 and TBC1D4 proteins in human skeletal muscle. J Physiol 592, 351-75
24247980   Curated Info

78

Peng B, et al. (2014) Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells. BMC Cancer 14, 146
24589236   Curated Info

79

Nardi F, et al. (2014) Enhanced Insulin Sensitivity Associated with Provision of Mono and Polyunsaturated Fatty Acids in Skeletal Muscle Cells Involves Counter Modulation of PP2A. PLoS One 9, e92255
24632852   Curated Info

80

Nguyen le XT, Mitchell BS (2013) Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc Natl Acad Sci U S A 110, 20681-6
24297901   Curated Info

81

Piovan E, et al. (2013) Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell 24, 766-76
24291004   Curated Info

82

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

83

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

84

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

85

Risso G, et al. (2013) Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle 12, 3165-74
24013425   Curated Info

86

Li Y, Huang X, Zhang Q, Ma K (2013) Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials. Mol Med Rep 8, 655-61
23778885   Curated Info

87

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

88

Zhang P, et al. (2013) Identification and functional characterization of p130Cas as a substrate of protein tyrosine phosphatase nonreceptor 14. Oncogene 32, 2087-95
22710723   Curated Info

89

Zhao R, et al. (2013) CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle 12, 935-43
23421998   Curated Info

90

Munoz C, et al. (2013) Up-regulation of the inwardly rectifying K⁺ channel Kir2.1 (KCNJ2) by protein kinase B (PKB/Akt) and PIKfyve. J Membr Biol 246, 189-97
23188060   Curated Info

91

Sourbier C, et al. (2013) Englerin A stimulates PKCθ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer Cell 23, 228-37
23352416   Curated Info

92

Chen S, et al. (2013) Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases. Sci Signal 6, ra40
23716717   Curated Info

93

Ersoy BA, et al. (2013) Phosphatidylcholine transfer protein interacts with thioesterase superfamily member 2 to attenuate insulin signaling. Sci Signal 6, ra64
23901139   Curated Info

94

Gulen MF, et al. (2012) Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity 37, 800-12
23142783   Curated Info

95

Villagrasa P, et al. (2012) Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 31, 4022-33
22158034   Curated Info

96

Liu M, et al. (2012) Phosphorylation of Adaptor Protein Containing Pleckstrin Homology Domain, Phosphotyrosine Binding Domain, and Leucine Zipper Motif 1 (APPL1) at Ser430 Mediates Endoplasmic Reticulum (ER) Stress-induced Insulin Resistance in Hepatocytes. J Biol Chem 287, 26087-93
22685300   Curated Info

97

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

98

Misra UK, Pizzo SV (2012) Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. J Cell Biochem 113, 1488-500
22173835   Curated Info

99

Schmitt JM, Smith S, Hart B, Fletcher L (2012) CaM kinase control of AKT and LNCaP cell survival. J Cell Biochem 113, 1514-26
22173970   Curated Info

100

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

101

Li P, et al. (2012) P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation. Mol Biol Cell 23, 1582-92
22357623   Curated Info

102

Mulhern D (2012) CST Curation Set: 13939; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

103

Singh AM, et al. (2012) Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-26
22385658   Curated Info

104

Gupta M, et al. (2012) Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119, 476-87
22080480   Curated Info

105

Zheng Y, Asara JM, Tyner AL (2012) Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrate. J Biol Chem 287, 148-58
22084245   Curated Info

106

Wang S, et al. (2012) Extensive Crosstalk between O-GlcNAcylation and Phosphorylation Regulates Akt Signaling. PLoS One 7, e37427
22629392   Curated Info

107

Rikova K (2011) CST Curation Set: 13129; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

108

Rikova K (2011) CST Curation Set: 13131; Year: 2011; Biosample/Treatment: cell line, MGH-9/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

109

Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9
21059620   Curated Info

110

Liu J, et al. (2011) PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 31, 4917-27
21986499   Curated Info

111

Chen CH, Sarbassov dos D (2011) The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J Biol Chem 286, 40386-94
21965657   Curated Info

112

Warfel NA, Niederst M, Newton AC (2011) Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286, 39122-9
21908613   Curated Info

113

Lu Y, et al. (2011) Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 30, 4567-77
21666717   Curated Info

114

Hiraoka D, Okumura E, Kishimoto T (2011) Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt. Oncogene 30, 4487-97
21577208   Curated Info

115

Yuan J, et al. (2011) PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 10, 2189-99
21750219   Curated Info

116

Su CH, et al. (2011) Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal 23, 1824-30
21767636   Curated Info

117

Lodeiro M, et al. (2011) The SHP-1 protein tyrosine phosphatase negatively modulates Akt signaling in the ghrelin/GHSR1a system. Mol Biol Cell 22, 4182-91
21900501   Curated Info

118

Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286, 37389-98
21908616   Curated Info

119

Xiao L, et al. (2011) KIBRA Protein Phosphorylation Is Regulated by Mitotic Kinase Aurora and Protein Phosphatase 1. J Biol Chem 286, 36304-15
21878642   Curated Info

120

Pierre F, et al. (2011) Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 356, 37-43
21755459   Curated Info

121

Roy D, Dittmer DP (2011) Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 179, 2108-19
21819957   Curated Info

122

Haque A, et al. (2011) Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147, 185-98
21962515   Curated Info

123

Ohta E, Kawakami F, Kubo M, Obata F (2011) LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett 585, 2165-70
21658387   Curated Info

124

Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

125

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

126

Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

127

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

128

Wang H, et al. (2011) Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-β-signaling pathways regulates the innate inflammatory response. J Immunol 186, 5217-26
21422248   Curated Info

129

Kwiatkowska A, et al. (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813, 655-67
21276823   Curated Info

130

Xie X, et al. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 108, 6474-9
21464307   Curated Info

131

Saci A, Cantley LC, Carpenter CL (2011) Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 42, 50-61
21474067   Curated Info

132

Korolchuk VI, et al. (2011) Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol 13, 453-60
21394080   Curated Info

133

Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9
21177249   Curated Info

134

Nagashima K, et al. (2011) Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-48
21118801   Curated Info

135

Ou YH, et al. (2011) TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation. Mol Cell 41, 458-70
21329883   Curated Info

136

Jensen J, et al. (2011) Effects of adrenaline on whole-body glucose metabolism and insulin-mediated regulation of glycogen synthase and PKB phosphorylation in human skeletal muscle. Metabolism 60, 215-26
20153492   Curated Info

137

Frederick MJ, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178, 548-71
21281788   Curated Info

138

Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71
21215704   Curated Info

139

Vind BF, et al. (2011) Impaired insulin-induced site-specific phosphorylation of TBC1 domain family, member 4 (TBC1D4) in skeletal muscle of type 2 diabetes patients is restored by endurance exercise-training. Diabetologia 54, 157-67
20938636   Curated Info

140

Yang NY, et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23, 201-12
20837138   Curated Info

141

Yung HW, Charnock-Jones DS, Burton GJ (2011) Regulation of AKT phosphorylation at Ser473 and Thr308 by endoplasmic reticulum stress modulates substrate specificity in a severity dependent manner. PLoS One 6, e17894
21445305   Curated Info

142

Shibata MA, et al. (2011) α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation. BMC Med 9, 69
21639868   Curated Info

143

Paweletz CP, et al. (2011) Identification of direct target engagement biomarkers for kinase-targeted therapeutics. PLoS One 6, e26459
22039492   Curated Info

144

Sundaresan NR, et al. (2011) The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4, ra46
21775285   Curated Info

145

Yang S, Xiao X, Meng X, Leslie KK (2011) A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6, e26343
22039466   Curated Info

146

Siddiqui-Jain A, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70, 10288-98
21159648   Curated Info

147

Hoang B, et al. (2010) Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560-8
20686120   Curated Info

148

Xiao L, et al. (2010) Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation. Cell Death Differ 17, 1448-62
20186153   Curated Info

149

Shen X, Xi G, Radhakrishnan Y, Clemmons DR (2010) PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-i-stimulated AKT activation and vascular smooth muscle cell survival. J Biol Chem 285, 29416-24
20643654   Curated Info

150

Zheng Y, et al. (2010) Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 30, 4280-92
20606012   Curated Info

151

Qiang L, Banks AS, Accili D (2010) Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J Biol Chem 285, 27396-401
20519497   Curated Info

152

Finnegan S, Mackey AM, Cotter TG (2010) A stress survival response in retinal cells mediated through inhibition of the serine/threonine phosphatase PP2A. Eur J Neurosci 32, 322-34
20636478   Curated Info

153

Bunkholt Elstrand M, et al. (2010) Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 41, 794-804
20153512   Curated Info

154

Banerjee A, et al. (2010) Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol 84, 5936-46
20357092   Curated Info

155

Carnevalli LS, et al. (2010) S6K1 plays a critical role in early adipocyte differentiation. Dev Cell 18, 763-74
20493810   Curated Info

156

Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285, 15076-87
20212043   Curated Info

157

Chen CC, et al. (2010) FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev Cell 18, 592-604
20412774   Curated Info

158

Calay D, et al. (2010) Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J Invest Dermatol 130, 1136-45
20054340   Curated Info

159

Mallon R, et al. (2010) Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther 9, 976-84
20371716   Curated Info

160

Nava P, et al. (2010) Interferon-gamma regulates intestinal epithelial homeostasis through converging beta-catenin signaling pathways. Immunity 32, 392-402
20303298   Curated Info

161

Bidinosti M, et al. (2010) Postnatal deamidation of 4E-BP2 in brain enhances its association with raptor and alters kinetics of excitatory synaptic transmission. Mol Cell 37, 797-808
20347422   Curated Info

162

Sheng Q, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17, 298-310
20227043   Curated Info

163

Moritz A (2010) CST Curation Set: 9280; Year: 2010; Biosample/Treatment: cell line, MKN-45/DMSO &'||' Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

164

Moritz A (2010) CST Curation Set: 9235; Year: 2010; Biosample/Treatment: cell line, MKN-45/calyculin_A & pervanadate; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

165

Moritz A (2010) CST Curation Set: 9241; Year: 2010; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

166

Singh A, et al. (2010) Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 21, 1140-52
20110348   Curated Info

167

Alberobello AT, et al. (2010) Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem 285, 6563-72
20044479   Curated Info

168

Moritz A (2010) CST Curation Set: 8838; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

169

Zhao Y, et al. (2010) Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T. Proc Natl Acad Sci U S A 107, 2592-7
20133777   Curated Info

170

Saavedra A, et al. (2010) PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ 17, 324-35
19745829   Curated Info

171

Seong HA, Jung H, Ichijo H, Ha H (2010) Reciprocal negative regulation of PDK1 and ASK1 signaling by direct interaction and phosphorylation. J Biol Chem 285, 2397-414
19920149   Curated Info

172

Moritz A (2010) CST Curation Set: 8865; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

173

Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70, 288-98
20028854   Curated Info

174

Eto I (2010) Upstream molecular signaling pathways of p27(Kip1) expression: Effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids. Cancer Cell Int 10, 3
20170512   Curated Info

175

De Toni-Costes F, et al. (2010) A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS One 5, e9807
20352103   Curated Info

176

Gu M, et al. (2009) Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 69, 9465-72
19920184   Curated Info

177

Davies MA, et al. (2009) Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15, 7538-7546
19996208   Curated Info

178

Bai D, Ueno L, Vogt PK (2009) Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125, 2863-70
19609947   Curated Info

179

Dong W, Albers JJ, Vuletic S (2009) Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res 87, 3176-85
19472218   Curated Info

180

Yang WL, et al. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134-8
19713527   Curated Info

181

Tzatsos A (2009) Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J Biol Chem 284, 22525-34
19561084   Curated Info

182

Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

183

Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

184

Miao H, et al. (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20
19573808   Curated Info

185

Chiang MH, et al. (2009) Mechanism of Hypoxia-induced GCM1 Degradation: IMPLICATIONS FOR THE PATHOGENESIS OF PREECLAMPSIA. J Biol Chem 284, 17411-9
19416964   Curated Info

186

Kim KY, et al. (2009) Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69, 4018-26
19366811   Curated Info

187

Yim EK, et al. (2009) Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15, 304-14
19345329   Curated Info

188

Park J, et al. (2009) DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. J Biol Chem 284, 6169-74
19144640   Curated Info

189

Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38
19209957   Curated Info

190

Kawase T, et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 136, 535-50
19203586   Curated Info

191

Guertin DA, et al. (2009) mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-59
19185849   Curated Info

192

Ihle NT, et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69, 143-50
19117997   Curated Info

193

Chabot C, et al. (2009) New role for the protein tyrosine phosphatase DEP-1 in Akt activation and endothelial cell survival. Mol Cell Biol 29, 241-53
18936167   Curated Info

194

Chua BT, et al. (2009) Regulation of Akt(ser473) phosphorylation by Choline kinase in breast carcinoma cells. Mol Cancer 8, 131
20042122   Curated Info

195

Monje PV, Athauda G, Wood PM (2008) Protein kinase A-mediated gating of neuregulin-dependent ErbB2-ErbB3 activation underlies the synergistic action of cAMP on Schwann cell proliferation. J Biol Chem 283, 34087-100
18799465   Curated Info

196

Koomoa DL, et al. (2008) Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma. Cancer Res 68, 9825-31
19047162   Curated Info

197

Higuchi M, Onishi K, Kikuchi C, Gotoh Y (2008) Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 10, 1356-64
18931661   Curated Info

198

Lee SB, et al. (2008) Nuclear Akt interacts with B23/NPM and protects it from proteolytic cleavage, enhancing cell survival. Proc Natl Acad Sci U S A 105, 16584-9
18931307   Curated Info

199

Hu Z, Chen J, Wei Q, Xia Y (2008) Bidirectional actions of hydrogen peroxide on endothelial nitric-oxide synthase phosphorylation and function: co-commitment and interplay of Akt and AMPK. J Biol Chem 283, 25256-63
18617528   Curated Info

200

Brummer T, et al. (2008) Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 27, 2305-16
19172738   Curated Info

201

Kinoshita H, et al. (2008) Roles of phosphatidylinositol 3-kinase-Akt and NADPH oxidase in adenosine 5'-triphosphate-sensitive K+ channel function impaired by high glucose in the human artery. Hypertension 52, 507-13
18678787   Curated Info

202

Zunder ER, et al. (2008) Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 14, 180-92
18691552   Curated Info

203

Austin RL, et al. (2008) siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57, 2066-73
18443205   Curated Info

204

Deep G, Oberlies NH, Kroll DJ, Agarwal R (2008) Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27, 3986-98
18332867   Curated Info

205

Hong F, et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30, 701-11
18570873   Curated Info

206

McDonald PC, et al. (2008) Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 68, 1618-24
18339839   Curated Info

207

Banerjee S, et al. (2008) Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 82, 2606-12
18160431   Curated Info

208

Jindra PT, Jin YP, Rozengurt E, Reed EF (2008) HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180, 2357-66
18250445   Curated Info

209

Dos Santos C, et al. (2008) A critical role for Lyn in acute myeloid leukemia. Blood 111, 2269-79
18056483   Curated Info

210

Harwood FC, Shu L, Houghton PJ (2008) mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem 283, 2575-85
18056704   Curated Info

211

Vojtechová M, et al. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 10, 99-107
18283331   Curated Info

212

Kuo YC, et al. (2008) Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 283, 1882-92
18042541   Curated Info

213

Yang KJ, et al. (2008) Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem 283, 1480-91
18024423   Curated Info

214

Zhou J (2008) CST Curation Set: 3677; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

215

Di Fulvio M, Frondorf K, Gomez-Cambronero J (2008) Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner. Cell Signal 20, 176-85
18006275   Curated Info

216

Ananthanarayanan B, Fosbrink M, Rahdar M, Zhang J (2007) Live-cell molecular analysis of Akt activation reveals roles for activation loop phosphorylation. J Biol Chem 282, 36634-41
17928291   Curated Info

217

Djouder N, et al. (2007) S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol Cell 28, 28-40
17936702   Curated Info

218

Selvendiran K, et al. (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282, 28609-18
17684018   Curated Info

219

Cen L, et al. (2007) PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer 97, 785-91
17848913   Curated Info

220

Khundmiri SJ, et al. (2007) Ouabain stimulates protein kinase B (Akt) phosphorylation in opossum kidney proximal tubule cells through an ERK-dependent pathway. Am J Physiol Cell Physiol 293, C1171-80
17634416   Curated Info

221

Han EK, et al. (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene 26, 5655-61
17334390   Curated Info

222

Odriozola L, Singh G, Hoang T, Chan AM (2007) Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282, 23306-15
17565999   Curated Info

223

Tzatsos A, Tsichlis PN (2007) Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282, 18069-82
17459875   Curated Info

224

Burelout C, Naccache PH, Bourgoin SG (2007) Dissociation between the translocation and the activation of Akt in fMLP-stimulated human neutrophils--effect of prostaglandin E2. J Leukoc Biol 81, 1523-34
17339610   Curated Info

225

Yuan G, et al. (2007) Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways. Endocrinology 148, 2016-26
17272402   Curated Info

226

Lee SB, et al. (2007) ATG1, an autophagy regulator, inhibits cell growth by negatively regulating S6 kinase. EMBO Rep 8, 360-5
17347671   Curated Info

227

Brognard J, Sierecki E, Gao T, Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-31
17386267   Curated Info

228

Wang C, et al. (2007) Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 282, 7991-6
17244624   Curated Info

229

Crellin NK, Garcia RV, Levings MK (2007) Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 109, 2014-22
17062729   Curated Info

230

Rocher G, Letourneux C, Lenormand P, Porteu F (2007) Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 282, 5468-77
17200115   Curated Info

231

Lerea KM, Venjara AY, Olson SC, Kelly MR (2007) Threonine phosphorylation of integrin beta3 in calyculin A-treated platelets is selectively sensitive to 5'-iodotubercidin. Biochim Biophys Acta 1773, 185-91
17052767   Curated Info

232

Lessmann E, et al. (2007) Oxysterol-binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation. Cell Signal 19, 384-92
16962287   Curated Info

233

Leslie NR, Yang X, Downes CP, Weijer CJ (2007) PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 17, 115-25
17240336   Curated Info

234

Opel D, et al. (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67, 735-45
17234785   Curated Info

235

Zagórska A, et al. (2007) Regulation of activity and localization of the WNK1 protein kinase by hyperosmotic stress. J Cell Biol 176, 89-100
17190791   Curated Info

236

Edling CE, et al. (2007) Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. Br J Haematol 136, 260-8
17156394   Curated Info

237

Choudhari SR, et al. (2007) Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 6, 112-21
17237271   Curated Info

238

Barragán M, et al. (2006) Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 80, 1473-9
16940331   Curated Info

239

Van Meter TE, Broaddus WC, Cash D, Fillmore H (2006) Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. Cancer 107, 2446-54
17041888   Curated Info

240

King TD, Gandy JC, Bijur GN (2006) The protein phosphatase-1/inhibitor-2 complex differentially regulates GSK3 dephosphorylation and increases sarcoplasmic/endoplasmic reticulum calcium ATPase 2 levels. Exp Cell Res 312, 3693-700
16987514   Curated Info

241

Rousseau S, et al. (2006) CXCL12 and C5a trigger cell migration via a PAK1/2-p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cell Signal 18, 1897-905
16574378   Curated Info

242

Sastry KS, Karpova Y, Kulik G (2006) Epidermal growth factor protects prostate cancer cells from apoptosis by inducing BAD phosphorylation via redundant signaling pathways. J Biol Chem 281, 27367-77
16847055   Curated Info

243

Wei Q, Xia Y (2006) Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 281, 21652-9
16737962   Curated Info

244

Jia W, et al. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4, 549-62
16908594   Curated Info

245

Chao OS, Clément MV (2006) Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells. Oncogene 25, 4458-69
16767165   Curated Info

246

Zhang XP, Hintze TH (2006) cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol 290, H2376-84
16428343   Curated Info

247

Gandy JC, Rountree AE, Bijur GN (2006) Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulin-like growth factor-1. FEBS Lett 580, 3051-8
16684529   Curated Info

248

Tomita Y, et al. (2006) Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12, 3070-7
16707604   Curated Info

249

Zeng Z, et al. (2006) Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66, 3737-46
16585200   Curated Info

250

Huang M, Kamasani U, Prendergast GC (2006) RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 25, 1281-9
16247449   Curated Info

251

Edwards LA, et al. (2006) Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther 5, 645-54
16546979   Curated Info

252

Wingate AD, Campbell DG, Peggie M, Arthur JS (2006) Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 393, 715-24
16223362   Curated Info

253

Wu Y, et al. (2006) Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells. Mol Cancer Ther 5, 246-52
16505097   Curated Info

254

Shao Z, et al. (2006) c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res 98, 111-8
16306447   Curated Info

255

Dorai T, et al. (2005) The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 41, 2935-47
16310354   Curated Info

256

Pim D, Massimi P, Dilworth SM, Banks L (2005) Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24, 7830-8
16044149   Curated Info

257

Jung HS, et al. (2005) Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19, 2748-59
15994200   Curated Info

258

Xu BE, et al. (2005) WNK1 activates SGK1 by a phosphatidylinositol 3-kinase-dependent and non-catalytic mechanism. J Biol Chem 280, 34218-23
16081417   Curated Info

259

de Alvaro C, Martinez N, Rojas JM, Lorenzo M (2005) Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell 16, 4454-61
16000370   Curated Info

260

Tremblay F, et al. (2005) Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 54, 2674-84
16123357   Curated Info

261

Weigert C, et al. (2005) Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 289, E251-7